Cipla Ltd — Q3 FY26
Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D s...
bearish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
Generic Revlimid contribution immaterial from Q3 FY26
Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1